Inotek Pharmaceuticals Corporation

Norman N Kim

William K McVicar

Prakash Jagtap

Rudolf A Baumgartner

The present invention is directed to a composition or a kit comprising a combination of a prostaglandin analog and an adenosine receptor Aagonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. In some embodiments, the adenosine receptor Aagonist is Compound A, ((2R,3S,4R,5R)-5-(6 -(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate, having the structure, 

Combination, kit and method of reducing intraocular pressure

Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).

Method of reducing intraocular pressure in humans

The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor Aagonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. In one embodiment, the prostaglandin analog is latanoprost and the adenosine receptor Aagonist is Compound A, ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate, having the structure, 

Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine Areceptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of timolol marketed under the brand Timoptic&#x2122; and Compound A.

Combination compositions for reducing intraocular pressure

Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine Areceptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of dorzolamide marketed under the brand Trusopt&#x2122; and Compound A.

Growing community of inventors

Westford, MA, United States of America

Norman N Kim